MedPageToday
MedPage Today) — CHICAGO — Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with a population largely in sinus rhythm, but small…
Read More
Is DOAC A Viable Option After Bioprosthetic Valve Surgery Even in Sinus Rhythm?
Elroy Kucera
03:19
MedPage Today) — CHICAGO — Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with a population largely in sinus rhythm, but small…
